Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 1.00 |
| ▸ | NPC1 | O15118 | 10/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 4/20 | 1.00 |
| ▸ | RELA | Q04206 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | CASP3 | P42574 | 4/20 | 0.74 |
| ▸ | SENP8 | Q96LD8 | 4/20 | 0.74 |
| ▸ | SENP7 | Q9BQF6 | 4/20 | 0.74 |
| ▸ | SENP6 | Q9GZR1 | 4/20 | 0.74 |
| ▸ | TP53 | P04637 | 4/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.68 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405003 | 0.85 | RAB9A (0.74) | RAB9ANPC1KDM4ESMN1; SMN2NFKB1 | |
| SCHEMBL4918421 | 0.83 | CASP3 (1.00) | RAB9ANPC1KDM4ESMN1; SMN2NFKB1 | |
| SCHEMBL4914385 | 0.82 | NPC1 (1.00) | RAB9ANPC1KDM4ESMN1; SMN2NFKB1 | |
| SCHEMBL6229059 | 0.81 | RAB9A (1.00) | RAB9ANPC1KDM4ESMN1; SMN2NFKB1 | |
| SCHEMBL30370064 | 0.81 | LRRK2 (1.00) | RAB9ANPC1KDM4ESMN1; SMN2NFKB1 | |
| SCHEMBL4395968 | 0.79 | RAB9A (0.80) | RAB9ANPC1KDM4ESMN1; SMN2NFKB1 | |
| SCHEMBL4401874 | 0.78 | RAB9A (1.00) | RAB9ANPC1KDM4ESMN1; SMN2NFKB1 | |
| SCHEMBL3787846 | 0.78 | DYRK1A (0.76) | RAB9ANPC1KDM4ESMN1; SMN2NFKB1 | |
| SCHEMBL19270401 | 0.78 | RAB9A (0.71) | RAB9ANPC1KDM4ESMN1; SMN2NFKB1 | |
| SCHEMBL6641942 | 0.77 | DYRK1A (0.74) | RAB9ANPC1KDM4ESMN1; SMN2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | RAB9A 3748/4885NPC1 2477/4885KDM4E 3311/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | RAB9A 3748/4885NPC1 2477/4885KDM4E 3311/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | RAB9A 4325/4885NPC1 3637/4885KDM4E 2080/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | RAB9A 4325/4885NPC1 3637/4885KDM4E 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.